Cediranib: Difference between revisions
Content deleted Content added
m Quick-adding category "Quinazolines" (using HotCat) |
Penmachine (talk | contribs) Also used for kidney cancer |
||
| Line 24: | Line 24: | ||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
}} |
}} |
||
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s. It is being developed by [[AstraZeneca]] as a possible chemotherapeutic agent for oral administration. |
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s. It is being developed by [[AstraZeneca]] as a possible anti-cancer chemotherapeutic agent for oral administration. |
||
As of 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]] and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. |
As of 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. |
||
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. |
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. |
||
Revision as of 00:55, 11 November 2008
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628 |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.5 g/mol g·mol−1 |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children.
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
Further reading
- Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |